Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Operating Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Operating Expenses for 6 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 6.55% to $13.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.0 million through Dec 2025, up 81.8% year-over-year, with the annual reading at $52.0 million for FY2025, 81.8% up from the prior year.
  • Operating Expenses for Q4 2025 was $13.8 million at Inhibikase Therapeutics, up from $12.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $14.6 million in Q1 2025, with the low at $4.0 million in Q2 2021.
  • Average Operating Expenses over 5 years is $6.9 million, with a median of $4.8 million recorded in 2021.
  • The sharpest move saw Operating Expenses surged 584.28% in 2021, then fell 20.07% in 2024.
  • Over 5 years, Operating Expenses stood at $5.0 million in 2021, then decreased by 12.79% to $4.4 million in 2022, then increased by 0.11% to $4.4 million in 2023, then surged by 193.6% to $12.9 million in 2024, then grew by 6.55% to $13.8 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $13.8 million, $12.8 million, and $10.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.